BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

786 related articles for article (PubMed ID: 34925375)

  • 1. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer.
    Chen Y; Zheng X; Wu C
    Front Immunol; 2021; 12():792691. PubMed ID: 34925375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer.
    Pecci F; Cantini L; Bittoni A; Lenci E; Lupi A; Crocetti S; Giglio E; Giampieri R; Berardi R
    Curr Treat Options Oncol; 2021 Jun; 22(8):69. PubMed ID: 34110510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1/PD-L1-dependent immune response in colorectal cancer.
    Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
    J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current advancements and future perspectives of immunotherapy in colorectal cancer research.
    Kishore C; Bhadra P
    Eur J Pharmacol; 2021 Feb; 893():173819. PubMed ID: 33347822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
    Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
    Front Immunol; 2020; 11():620166. PubMed ID: 33584714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in colorectal cancer.
    Agarwal P; Le DT; Boland PM
    Adv Cancer Res; 2021; 151():137-196. PubMed ID: 34148613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer.
    Chen Y; Liu C; Zhu S; Liang X; Zhang Q; Luo X; Yuan L; Song L
    Int Immunopharmacol; 2021 Jul; 96():107607. PubMed ID: 33831809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma.
    Almquist DR; Ahn DH; Bekaii-Saab TS
    BioDrugs; 2020 Jun; 34(3):349-362. PubMed ID: 32246441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism and strategies of immunotherapy resistance in colorectal cancer.
    Shan J; Han D; Shen C; Lei Q; Zhang Y
    Front Immunol; 2022; 13():1016646. PubMed ID: 36238278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal Cancer Immunotherapy: Options and Strategies.
    Johdi NA; Sukor NF
    Front Immunol; 2020; 11():1624. PubMed ID: 33042104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell-based immunotherapy in colorectal cancer.
    Feng M; Zhao Z; Yang M; Ji J; Zhu D
    Cancer Lett; 2021 Feb; 498():201-209. PubMed ID: 33129958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results and challenges of immune checkpoint inhibitors in colorectal cancer.
    Emambux S; Tachon G; Junca A; Tougeron D
    Expert Opin Biol Ther; 2018 May; 18(5):561-573. PubMed ID: 29471676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy.
    Kamal Y; Schmit SL; Frost HR; Amos CI
    Immunotherapy; 2020 Oct; 12(14):1083-1100. PubMed ID: 32787587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy and predictive immunologic profile: the tip of the iceberg.
    Cunha Pereira T; Rodrigues-Santos P; Almeida JS; RĂªgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G
    Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
    Thomas J; Leal A; Overman MJ
    Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
    Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.